MedTrace Logo

Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients

NCT05895123 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-08-01

No results posted yet for this study

Summary

STEMI is a serious type of coronary heart disease, which is a major cause of disability and death. Morphologically the key feature of remodeling is myocyte hypertrophy, myocyte loss from necrosis or apoptosis, as well as interstitial cell growth especially fibroblast proliferation leading to myocardial fibrosis .

Elevated serum LDL-cholesterol concentrations play a proatherogenic role by stimulating inflammation and oxidative processes.

Statins have been documented to retard fibrosis and ventricular hypertrophy by the cessation of myofibroblast activity. Clinical studies have proven that statins not only regulate lipids but also improve myocardial fibrosis, regulate cell proliferation and apoptosis, regulate ventricular remodeling, and protect the myocardium

Conditions

  • ST-segment Elevation Myocardial Infarction

Interventions

DRUG

Rosuvastatin 20 mg

patients will receive one tablet rosuvastatin 20 mg every night

DRUG

Atorvastatin 40mg

patients will receive one tablet Atorvastatin 40 mg every night

Sponsors & Collaborators

  • Alexandria University

    collaborator OTHER

  • Damanhour University

    lead OTHER

Principal Investigators

  • Zeinab M Elhadad, bachelor · demonstrator of Clinical Pharmacy, Damanhour University.

  • Amira B Kassem, PhD · Lecturer of Clinical Pharmacy, Damanhour University.

  • Ahmed salahaldin, PHD · Lecturer of biochemisrty, Damanhour University.

  • noha ahmad, PHD · Lecturer of Clinical Pharmacy, Damanhour University.

  • ahmad alamrawy, PHD · Lecturer of cardiology , Faculty of medicine, Alexandria University.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2023-03-01
Completion
2023-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05895123 on ClinicalTrials.gov